OXO-001: an innovative treatment that improves the success of women’s fertility by enhancing embryo implantation
We are currently developing OXO-001, a first-in class oral drug that acts directly on the endometrium to enhance and improve the embryo implantation process, which is a breakthrough innovation in reproductive medicine.
After having demonstrated its efficacy in preclinical trials and its safety in humans, Oxolife has already initiated a Phase II international clinical trial (OXOART2) with the drug. The main objective of this ongoing clinical trial is to demonstrate the efficacy of OXO-001 in increasing the pregnancy rate of infertile women.
The development of OXO-001 responds to an unmet medical problem that affects millions of women undergoing assisted reproduction worldwide, since there is no alternative on the market to prepare and improve the conditions of the endometrium for the embryo implantation process.
Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.
This clinical trial aims to test the capacity of OXO-001 to enhance embryo implantation. It is a phase II, randomised, double-blind, parallel-group, placebo-controlled trial that will assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.
Study Start Date:
September 1, 2021
Estimated Primary Completion Date:
October 1, 2022
Polycystic ovary syndrome
OXO-001: an innovative approach to PCOS infertility treatment
Another research with OXO-001 is an innovative approach to PCOS infertility treatment. Previous preclinical studies performed have shown OXO-001 is capable of recovering ovulation and fertility in an animal model with PCOS characteristics, and we are currently in late stages of the pre-clinical development for this condition.
In order to obtain more information about the mechanism of action of OXO-001 and its potential use as a treatment for infertility associated with PCOS, we have recently initiated a collaboration with the University of Cordoba (UCO) and the Maimonides Institute for Biomedical Research (IMIBIC), and with Rutgers, The State University of New Jersey.